ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need.
This website contains forward-looking statements about potential therapeutic uses and effects of ProQR Therapeutics’ products, including but not limited to our technologies.
At ProQR science is literally at the heart of what we do. Our passion lies in discovering the latest RNA technologies and translating them to life-changing treatments.
… leader who can navigate the complexities of early clinical-stage programs. In this role, the candidate will: … applications eg INDs/CTAs and manage the clinicaltrial approval processes. Ensure that the content, quality, …
… Senior Clinical Scientist ProQR Therapeutics is a biotechnology … our development organization in preparation to start clinical development of our Axiomer pipeline, as a result we … Excellent knowledge of GCP, clinical operations, clinicaltrials, translation from pre-clinical to phase 1, scientific …